Millions Share a Deadly Genetic Heart Risk. This Experimental Drug Could Be a Game Changer
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
MedPage Today on MSN3d
siRNA Agent Slashes Lipoprotein(a) Levels
Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ...
Healio3d
Lepodisiran lowers Lp(a) substantially with infrequent administration
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Medical Dialogues5d
APOC3 and LDL-C Lowering: A Promising Strategy for Heart Disease Prevention, Study Finds
China: A recent study has shed light on the role of genetically predicted lower levels of apolipoprotein C3 (APOC3) in ...